IDEAYA Biosciences vs Syndax Pharmaceuticals
IDYA and SNDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IDYA and SNDX compare
IDEAYA Biosciences is the larger company, worth 3.6 times as much as Syndax Pharmaceuticals ($3.1B against $844M).
Syndax Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −72.3% compared with −74.8% at IDEAYA Biosciences.
IDEAYA Biosciences scores higher on the StockData Score (9 against 3 for Syndax Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IDYA | SNDX |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $844M |
| Share price | $31.83 | $9.45 |
| Change, 1 year | −0.38% | −43.7% |
| Change, 5 years | 37.1% | −46.8% |
| Beta (5Y) | 0.78 | 1.07 |
| Employees | 145 | 298 |
| StockData Score | ||
| Total score | 9 (better) | 3 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 13.1× | 2.9× (better) |
| P/B | 2.6× | – |
| FCF yield | −3.7% | – |
| Fair value | $29.10 | – |
| Margin of safety | −9.4% | – |
| Growth | ||
| Revenue growth (TTM) | – | 160% |
| Revenue growth, 5Y average | 62.1% | 158% (better) |
| Profitability | ||
| Operating margin | −92.7% | −61.7% (better) |
| Net margin | −74.8% | −72.3% (better) |
| FCF margin | −48.6% | – |
| Return on equity | −16.2% (better) | −426% |
| Return on invested capital | −51.9% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −44660.0× |
| Current ratio | 10.45 (better) | 4.69 |
| Altman Z-score | 15.97 (better) | −2.28 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 106% | 121% |
| Held by insiders | 0.83% | 1.8% |
| Insider net buying, 12 months | $281K (better) | −$2.9M |
| Short interest, % of float | 8.6% | 21.6% |
Go deeper
- IDYA stock overview
- IDYA income statement
- IDYA valuation and score
- SNDX stock overview
- SNDX income statement
- SNDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.